News: Portfolio 2007
TetraLogic Pharmaceuticals Appoints Dr. Andrew Pecora to Its Board of Directors
(continued)
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held company focused on discovering and developing new oncology drugs. Its lead program, IAP antagonists, are in preclinical development and are slated to enter clinical trials during the second half of 2007. Other apoptosis related drug discovery programs are at an earlier stage of development. To date, TetraLogic has raised a total of $44 million through private financings. The Company's investors include Amgen Ventures, HealthCare Ventures, Kammerer Associates, Latterell Venture Partners, PA Early Stage Partners, Quaker BioVentures and the Vertical Group. For additional information, please refer to the Company's website at www.tetralogicpharma.com.